Estring can be used long-term, and for many women, ongoing use is both expected and appropriate. Each ring stays in place for 90 days before being replaced with a new one, and because the condition it treats (vaginal dryness and irritation from menopause) is chronic and progressive, there is no standard cutoff point where you must stop. The North American Menopause Society’s 2022 position statement explicitly notes that the usual discussions about limiting the duration of hormone therapy do not apply to low-dose vaginal estrogen products like Estring.
That said, “long-term use is generally fine” comes with some important context depending on your medical history, whether you still have a uterus, and what symptoms you’re treating.
How the 90-Day Cycle Works
Estring is a flexible vaginal ring that releases approximately 7.5 micrograms of estradiol per day. It contains 2 mg of estradiol total, metered out at that low daily dose over the full 90-day period. You insert it into the upper part of the vaginal canal, leave it in continuously for three months, then remove it and insert a fresh ring if you’re continuing treatment. There’s no break needed between rings.
The dose is very low compared to systemic hormone therapy (pills, patches, or higher-dose vaginal rings designed to treat hot flashes). Estring is designed to work locally on vaginal tissue, and its systemic absorption is minimal. In clinical studies, it produced no endometrial overstimulation in any of the 58 women with a uterus who used it, compared to an 11 percent rate with estrogen vaginal cream.
Why There’s No Fixed Time Limit
The symptoms Estring treats, collectively called genitourinary syndrome of menopause, don’t resolve on their own. Unlike hot flashes, which often fade over time, vaginal dryness, burning, painful intercourse, and urinary irritation tend to worsen the longer you’re postmenopausal. Stopping treatment usually means symptoms return. This is why menopause specialists treat it as a chronic condition requiring ongoing management rather than a short course of therapy.
The FDA label advises using estrogen “at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.” For Estring specifically, the label states the ring should be replaced with a new one after 90 days “if continuation of therapy is deemed appropriate.” This language reflects the general principle that you and your prescriber should periodically reassess whether you still need it, not that there’s a hard expiration date on treatment.
Do You Need a Progestogen With It?
One of the key safety questions with any estrogen therapy is whether it stimulates the uterine lining enough to raise the risk of endometrial cancer. With oral or high-dose estrogen, women who still have a uterus typically need a progestogen to counteract that stimulation. With Estring, the picture is different. Clinical trial data showed zero percent endometrial overstimulation among Estring users, suggesting the dose is too low to meaningfully affect the uterine lining.
Most clinical guidelines do not require routine progestogen use alongside low-dose vaginal estrogen like Estring. However, the FDA label notes that warnings associated with oral estrogen therapy “should be considered in the absence of comparable data” for other forms. In practice, this means your prescriber may still want to monitor your endometrial health periodically, especially with very long-term use spanning many years. If you’ve had a hysterectomy, endometrial concerns don’t apply to you at all.
Who Should Not Use Estring
Certain medical histories rule out Estring use entirely, regardless of duration. These include:
- Known or suspected breast cancer, or a history of breast cancer
- Undiagnosed abnormal vaginal bleeding
- Active or past blood clots (deep vein thrombosis, pulmonary embolism, stroke, or heart attack)
- Known blood clotting disorders such as protein C, protein S, or antithrombin deficiency
- Liver disease or significant liver impairment
- Pregnancy
Several other conditions call for extra caution rather than an outright ban. Women with very high triglycerides, hereditary angioedema, poorly controlled asthma, epilepsy, migraines, or lupus may find that estrogen, even at low doses, can worsen their condition. These situations call for closer monitoring and a more frequent reassessment of whether to continue.
Structural Considerations
The ring itself sits in the vagina, so certain anatomical factors can affect comfort and safety over time. Women with a narrow vagina, vaginal stenosis, or pelvic organ prolapse may be more prone to irritation or ulceration from the ring. If you notice new vaginal discomfort, unusual discharge, or irritation while using Estring, that’s worth reporting to your prescriber. It may indicate the ring is pressing against tissue in a way that needs attention, not necessarily that you need to stop estrogen therapy altogether (a cream or tablet might work better in those cases).
If you’ve had a hysterectomy, Estring is still an option. One consideration: in rare cases, women with residual endometrial tissue after hysterectomy have experienced abnormal changes with estrogen-alone therapy. If your prescriber knows you have residual endometriosis, they may recommend adding a progestogen.
What Long-Term Use Looks Like in Practice
Many women use Estring for years, replacing the ring every 90 days on a rolling basis. There’s no evidence-based reason to take periodic breaks or to stop after a set number of years, as long as it’s still helping and your health profile hasn’t changed. A reasonable approach is to check in with your prescriber annually to confirm your symptoms still warrant treatment and that no new health concerns have emerged that would change the risk calculus.
The most practical thing to keep track of is your replacement schedule. Each ring lasts exactly 90 days. After that, the estradiol supply is depleted and symptoms will gradually return. Setting a calendar reminder for your swap date keeps the therapy consistent and your symptoms controlled.